Boston Scientific Jumps On Positive Surprise On Farapulse For AFIB Ablation
Portfolio Pulse from The Arora Report
Boston Scientific's stock (NYSE:BSX) has risen by 6.25% to $53.92 due to positive results from the ADVENT study on Farapulse Pulsed Field Ablation, a system for heart tissue ablation in atrial fibrillation patients. The system is expected to receive approval by next year. Boston Scientific, which also produces pacemakers, defibrillators, and stents, is benefiting from an aging population.
August 28, 2023 | 3:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Boston Scientific's stock has risen due to positive results from the Farapulse study. The system is expected to be approved next year, which could further boost the stock.
The positive results from the Farapulse study have already caused Boston Scientific's stock to rise. If the system receives approval next year, this could lead to increased sales and further boost the stock. Additionally, the company is benefiting from an aging population, which could lead to increased demand for its products.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100